Journal of Surgery Concepts & Practice >

2024 , Vol. 29 >Issue 04: 336 - 344

DOI: https://doi.org/10.16139/j.1007-9610.2024.04.11

Original article

Correlationship between total proteins SUMOylation and papillary thyroid carcinoma in males

  • WU Qiao ,
  • LIU Wei ,
  • ZHENG Jiaojiao ,
  • WANG Cong ,
  • AI Zhilong
Expand
  • Department of Thyroid-Breast Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Received date: 2023-03-20

  Online published: 2024-11-15

Fold

Abstract

Objective To investigate the relationship between protein SUMOylation level and the prognosis of papillary thyroid carcinoma(PTC) in males. Methods Protein SUMOylation levels in PTC was analyzed by bioinformatics based on GTEx and TCGA databases and validated by immunohistochemical staining and Western blotting in our clinical pairs specimens. The mRNA expression of the protein SUMOylation associated genes were measured by fluorescent quantitative real-time polymerase chain reaction (qRT-PCR) in surgical pairs specimens. Results The expression level of SUMOylation in the tumor tissues of PTC showed an elevated trend（P<0.05）, and was associated with poor prognosis of the patients by TCGA and GTEx databases analysis(P=0.021）. In the clinical samples of our hospital, it was verified that the level of SUMOylation in tumor tissues was higher than that of the paired non-tumor tissues（P<0.05）. However, qRT-PCR showed no significant changes in the transcriptional level of the protein SUMOylation associated genes in most cases. Conclusions Protein SUMOylation in thyroid tumor tissues were higher than that in paired non-tumor tissues, and the higher SUMOylation levels levels in tumor tissues were, the shorter overall survival time of the patients was.

Key words： SUMOylation; Males; Papillary thyroid carcinoma (PTC)

Cite this article

WU Qiao , LIU Wei , ZHENG Jiaojiao , WANG Cong , AI Zhilong . Correlationship between total proteins SUMOylation and papillary thyroid carcinoma in males[J]. Journal of Surgery Concepts & Practice, 2024 , 29(04) : 336 -344 . DOI: 10.16139/j.1007-9610.2024.04.11

References

[1] 田文. 甲状腺癌诊治之中国经验与未来走向[J]. 临床外科杂志, 2020, 28(3):201-204.
  TIAN W. Chinese experience and future trends in the diagnosis and treatment of thyroid cancer[J]. J Clin Surg, 2020, 28(3):201-204.
[2] 田文, 郗洪庆. 分化型甲状腺癌外科诊疗进展及展望[J]. 中国实用外科杂志, 2020, 40(1):78-82.
  TIAN W, XI H Q. Progress and prospects of surgical diagnosis and treatment of differentiated thyroid cancer[J]. Chin J Pract Surg, 2020, 40(1):78-82.
[3] LI M, DAL MASO L, VACCARELLA S. Global trends in thyroid cancer incidence and the impact of overdiagnosis[J]. Lancet Diabetes Endocrinol, 2020, 8(6):468-470.
[4] MAMMEN J S R, CAPPOLA A R. Autoimmune thyroid disease in women[J]. JAMA, 2021, 325(23):2392-2393.
[5] LUNDGREN C I, HALL P, DICKMAN P W, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study[J]. Cancer, 2006, 106(3):524-531.
[6] HAN Z J, FENG Y H, GU B H, et al. The post-translational modification, SUMOylation, and cancer (Review)[J]. Int J Oncol, 2018, 52(4):1081-1094.
[7] BECARES N, GAGE M C, PINEDA-TORRA I. Posttranslational modifications of lipid-activated nuclear receptors: focus on metabolism[J]. Endocrinology, 2017, 158(2):213-225.
[8] SEELER J S, DEJEAN A. SUMO and the robustness of cancer[J]. Nat Rev Cancer, 2017, 17(3):184-197.
[9] CUI W, SUN M, ZHANG S, et al. A SUMO-acetyl switch in PXR biology[J]. Biochim Biophys Acta, 2016, 1859(9):1170-1182.
[10] DE CRISTOFARO T, MASCIA A, PAPPALARDO A, et al. Pax8 protein stability is controlled by sumoylation[J]. J Mol Endocrinol, 2009, 42(1):35-46.
[11] FLOTHO A, MELCHIOR F. Sumoylation: a regulatory protein modification in health and disease[J]. Annu Rev Biochem, 2013,82:357-385.
[12] DAVIES L, WELCH H G. Current thyroid cancer trends in the United States[J]. JAMA Otolaryngol Head Neck Surg, 2014, 140(4):317-322.
[13] Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma[J]. Cell, 2014, 159(3):676-690.
[14] MONGELLI M N, GIRI S, PEIPERT B J, et al. Financial burden and quality of life among thyroid cancer survivors[J]. Surgery, 2020, 167(3):631-637.
[15] AL-QURAYSHI Z, FARAG M, SHAMA M A, et al. Total thyroidectomy versus lobectomy in small nodules suspicious for papillary thyroid cancer: cost-effectiveness analysis[J]. Laryngoscope, 2020, 130(12):2922-2926.
[16] DE ANDRADE J P, LORENZEN A W, WU V T, et al. Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer[J]. Oncotarget, 2017, 8(70):114801-114815.
[17] KESSLER J D, KAHLE K T, SUN T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis[J]. Science, 2012, 335(6066):348-353.
[18] BIEDERST?DT A, HASSAN Z, SCHNEEWEIS C, et al. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype[J]. Gut, 2020, 69(8):1472-1482.
[19] G?TEL P, PIECHACZYK M, BOSSIS G. Ubiquitin, SUMO, and Nedd8 as therapeutic targets in cancer[J]. Adv Exp Med Biol, 2020,1233:29-54.
Options
Outlines

/

〈 〉